CaMMouflage

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
50 patients (estimated)
Sponsors
Caribou Biosciences, Inc.
Tags
CAR T Cell (Allogeneic), B-Cell Maturation Antigen (BCMA)
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1351
NCT Identifier
NCT05722418

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.